Toxicity of pemetrexed during renal impairment explained—Implications for safe treatment-Reference-Cited by-同舟云学术

Toxicity of pemetrexed during renal impairment explained—Implications for safe treatment

Published:2021-07-07 Issue:8 Volume:149 Page:1576-1584
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Boosman René J.¹^ORCID,Dorlo Thomas P. C.¹,Rouw Nikki²³,Burgers Jacobus A.⁴,Dingemans Anne‐Marie C.⁵⁶,Heuvel Michel M.⁷,Hendriks Lizza E. L.⁵,Biesma Bonne⁸,Aerts Joachim G. J. V.⁶,Croes Sander⁹,Mathijssen Ron H. J.¹⁰,Huitema Alwin D. R.¹¹¹¹²,Heine Rob²

Affiliation:

1. Department of Pharmacy & Pharmacology Antoni van Leeuwenhoek—The Netherlands Cancer Institute Amsterdam The Netherlands

2. Department of Pharmacy, Radboud Institute for Health Sciences Radboud University Medical Center Nijmegen The Netherlands

3. Department of Pharmacy Jeroen Bosch Hospital 's‐Hertogenbosch The Netherlands

4. Department of Thoracic Oncology The Netherlands Cancer Institute Amsterdam The Netherlands

5. Department of Pulmonary Diseases, GROW—School for Oncology and Developmental Biology Maastricht University Medical Centre Maastricht The Netherlands

6. Department of Pulmonology Erasmus MC Rotterdam The Netherlands

7. Department of Pulmonology Radboud university medical center Nijmegen The Netherlands

8. Department of Pulmonary Diseases Jeroen Bosch Hospital 's Hertogenbosch The Netherlands

9. Department of Clinical Pharmacy & Toxicology Maastricht University Medical Centre Maastricht The Netherlands

10. Department of Medical Oncology Erasmus Medical Center Cancer Institute Rotterdam The Netherlands

11. Department of Clinical Pharmacy Utrecht University Medical Center, Utrecht University Utrecht The Netherlands

12. Department of Pharmacology Princess Máxima Center for Pediatric Oncology Utrecht The Netherlands

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.33721

Reference37 articles.

1. Metastatic non‐small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow‐up;Plachard D;Ann Oncol,2018

2. Malignant pleural mesothelioma: ESMO clinical practice guidelines for diagnosis, treatment and follow‐up;Baas P;Ann Oncol,2015

3. A phase II study of pemetrexed in patients with recurrent thymoma and thymic carcinoma;Gbolahan OB;J Thorax Oncol,2018

4. Effect of renal function on pemetrexed‐induced haematotoxicity;Ando Y;Cancer Chemother Pharmacol,2016

5. A semimechanistic‐physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy;Latz JE;Cancer Chemother Pharmacol,2006

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sarcopenia as a Predictive Factor for Carboplatin Toxicity in Patients with Advanced Non-Small Cell Lung Cancer;Nutrition and Cancer;2024-07-26

2. Effects of single nucleotide polymorphisms of the folylpolyglutamate synthase gene on pemetrexed administration‐induced nephropathy;British Journal of Clinical Pharmacology;2023-08-07

3. Folinic Acid to Prevent Pemetrexed-Associated Neutropenia After Intrathecal Administration: A Quick Win;Journal of Thoracic Oncology;2023-08

4. Renal function-based versus standard dosing of pemetrexed: a randomized controlled trial;Cancer Chemotherapy and Pharmacology;2022-11-21

5. Prediction of the pharmacokinetics of pemetrexed with a low test dose: A proof‐of‐concept study;British Journal of Clinical Pharmacology;2022-09-21